AstraZeneca: EU approves Enhertu in lung cancer
(CercleFinance.com) - AstraZeneca and Daiichi Sankyo announce that their Enhertu (trastuzumab deruxtecan) has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor a HER2-activating mutation (ERBB2).
Approval by the European Commission follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is based on the results of a Phase II trial.
Enhertu is the first HER2-directed therapy to demonstrate robust and durable results for these patients, and this EU approval marks an important milestone in the way the disease can be treated, a related source said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Approval by the European Commission follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is based on the results of a Phase II trial.
Enhertu is the first HER2-directed therapy to demonstrate robust and durable results for these patients, and this EU approval marks an important milestone in the way the disease can be treated, a related source said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.